Clearmind to Commence Clinical Trial in Alcohol-Use Disorder

Psychedelic drug company, Clearmind Medicine Inc. (Nasdaq: CMND), has received approval from the Israeli Ministry of Health to commence its Phase 1/2a clinical trial for alcohol use disorder (AUD) patients.

“This is the most important milestone for the company to date and marks our transition to a clinical- stage pharmaceutical company. The Clearmind team has been working tirelessly on the research and development of a novel treatment to the global epidemic of alcoholism. We are eager to continue our work with patients in need of help,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. “We believe that our non-hallucinogenic, psychedelic solution could be the answer to the global need for dedicated and effective treatments for addictions.”

MEAI, the active ingredient in CMND-100, is an innovative, psychoactive and non-hallucinogenic molecule that has been reported to reduce the desire to consume alcoholic beverages, while exerting a slight euphoric alcohol-like experience.

Highlights

Clearmind’s lead product candidate, CMND-100, a proprietary MEAI-based (5-methoxy-2-aminoindane) oral capsule, has been shown to be safe and effective in preclinical studies.

Clearmind will evaluate CMND-100 in a  multinational, multi-center, single and multiple dose tolerability, safety and pharmacokinetic study of CMND-100 in healthy volunteers and AUD subjects.

The study will establish a tolerable dose and evaluate safety, pharmacokinetics and pharmacodynamics of CMND-100. It will also look to demonstrate the preliminary efficacy of CMND-100 in reduction of drinking patterns and cravings in individuals with moderate-to-severe AUD.

An estimated 18 million adult Americans have AUD.

About Clearmind Medicine Inc.

Clearmind is a clinical- stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of fifteen patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.